The Impact of Cell Penetrating Peptides in Prospective Cancer Therapy: A Review

By

Zannatul Nashrah
19146072

A thesis submitted to the School of Pharmacy in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy

School of Pharmacy
BRAC University
February, 2023

Declaration

It is hereby declared that

1. The thesis submitted is my/our own original work while completing degree at Brac University.
2. The thesis does not contain material previously published or written by a third party, except where this is appropriately cited through full and accurate referencing.
3. The thesis does not contain material which has been accepted, or submitted, for any other degree or diploma at a university or other institution.
4. I have acknowledged all main sources of help

Student's Full Name & Signature:

Zannatul Nashrah
19146072

Approval

The thesis titled –The Impact of Cell-Penetrating Peptides in Prospective Cancer Therapy: A Review ‖ submitted by Zannatul Nashrah (19146072) of Spring, 2019 has been accepted as satisfactory in partial fulfillment of the requirement for the degree of Bachelor of Pharmacy.

Supervised By:

_____

Sabrina Sharmin, Phd
Assistant Professor
School of Pharmacy
BRAC University

Approved By:

Program Director:

_____

Professor Dr. Hasina Yasmin
Program Director and Assistant Dean
School of Pharmacy
BRAC University

Dean:

_____

Professor Dr. Eva Rahman Kabir
Dean
School of Pharmacy
BRAC University

Ethics Statement

This study does not involve any human and animal trial.

Executive Summary

Cell penetrating peptides have been identified as a viable tool for therapeutic use in the era of biomedicines and specialized carrier systems. Similar to other therapeutic peptides, peptide stability- the bottleneck for this class of biodegradable molecules will play a critical role inthe effective in vivo deployment of CPPs. Peptide-based administration could improve drug uptake in tumor cells, increasing the effectiveness of either conventional small-molecule medications or oligonucleotide-based treatments. To facilitate the achievement of therapeutic interventions, a thorough understanding of the cancer applications of cell penetrating peptidesas delivery systems is stressed; including various aspects of drug loading, cargoes, and delivery are discussed along with techniques for targeted delivery, activatable cell-penetratingpeptides, and transducible agents coupled to cell-penetrating peptides. Limitations and possible solutions invented are also mentioned.

Keyword: Cancer, cancer penetrating peptides, drug delivery, oligonucleotides, siRNA, therapies, CPP.

Dedication

Dedicated to my parents

Acknowledgement

Firstly, I want to thank the Almighty for his countless blessings, which have been provided to me in an effort to give me the tenacity and resolve to finish this project.

It gives me great pleasure to express my sincere gratitude to my academic supervisor, Sabrina Sharmin (Assistant Professor at the Department of Pharmacy at BRAC University), for her tremendous support and encouragement throughout my study. She was a genuine source of guidance and support for me throughout the duration of my study and project writing. She provided me with a lot of useful feedback and suggestions when I was studying, and I am really appreciative of that because it enabled me to finish my assignment on time. I also want to express my sincere gratitude to Dr. Eva Rahman Kabir, dean of the pharmacy department at Brac University, for her leadership, contribution and everything that she does for the department and the students.

Finally, I'd like to thank my family for always motivating me to stretch outside my comfort zone. Without the prayers and unwavering love of my family and loved ones, I would not have progressed this far. The people who always went above and beyond to help me whenever they were asked are likewise deserving of my appreciation

Table of Contents

List of Tables:

List of Figures:

List of Acronyms

CPP	Cell penetrating peptides
TAT	CPP from HIV transcription factor
TPP	Tumor targeting peptides
siRNA	Small interfering RNA
Dox	Doxorubicin
ACPPs	Activable CPPs
NF-jB	Stimulus-induced nuclear factor-jB
PTX	Paclitaxel
MPG	Human Synthetic N-Methylpurine-DNA Glycosylase
SynB1	Bio-synthetic CPP
Pep-1	Synthetic CPP
pVEC	CPP from murine vascular endothelian cadherin
CTT	CPP-targeted treatment
Antp	Antennapedia peptide
PEGA	Polyethylene glycol polyacrylamide copolymer
uPA	Urokinase plasminogen activator
MMPs	Matrix metalloproteinases
CAPs	Cancer associated proteases
MTX	Methotrexate
MMP-2	Metalloproteinase-2
NoPe	Novel Peptide
CREKA	Cysteine-arginine-glutamic acid-lysine-alanine
MCF-7	Michigan Cancer Foundation-7

R8	Polyarginine
PEI-CyD	Polyethylenimine-beta-cyclodextrin
pDNA	Plasmid DNA
P21	Tumor suppressor protein
ODD-Gal	Oxygen dependent destruction - galactosidase
EC-50	Half maximum effective concentration
BBB	Blood brain barrier
HIF-1	Hypoxia inducible factor-1
PNA	Peptide nucleic acid
HUVEC	Human umbilical vein endothelial cells
HIF-1	Hypoxia inducible factor-1
CHO	Chinese hamster ovary cancer cells
GAGs	Glycosaminoglycans
FA	Folic Acid
YTA2	Synthetic CPP
RVG	Rabies virus glycoprotein
IgG	Immunoglobulin G
IP	Intraperitoneal
MDA-MB-231	Human mammary carcinoma
MMTV	Mouse mammary tumor virus-
PyMT	Polyoma middle tumor antigen

Chapter 01

Introduction

The ineffectiveness of currently existing treatments for cancer could one day be overcome by adopting more potent therapeutic macromolecules, such as proteins or DNA. Cell-penetrating peptides offer a viable answer to the issues with drug distribution that are frequently encountered with traditional cancer chemotherapeutics and oligonucleotide-based treatments. Cell-penetratingpeptides that are not too long move independently or in combination with cargo through the cellular plasma membrane. The use of traditional chemotherapeutic agents is severely constrained. For instance, when treating metastatic melanoma, the medications may cause additional malignancies or tumors may become resistant to treatment and relapse. Drugs that mayselectively kill cancer cells i.e., successfully treat slow-growing and dormant cells without triggering chemo resistance mechanisms remain in high demand. Tamoxifen, as an example, raises the risk of endometrial cancer to grow in persons with breast cancer. These restrictions limit the application of chemotherapy, pharmacological therapies for cancer**.** Peptides may be helpful for medication development and discovery, according to an increasing number of studies. To boost efficacy, peptide with biological active regions might be joined together. They may also serve as vehicles for medications used in therapeutic strategies, such as chemotherapeutic. Peptides are attractive prospects for cancer treatment because of their non-immunogenicity, ability of simple modification, very good tissue invasion and inexpensive manufacturing costs, and simplicity of modification to increase bioactivity and in vivo performance in (Yavari et al.,n.d.) CPPs typically range in length from 5 to 30 amino acids, frequently have side chains made up of simple amino acids, and are frequently amphipathic. The earliest CPPs were created from natural sources proteins, like TAT from HIV-TAT and penetratin from Antennapedia's homeodomain (Regberg et al., 2012).

1.1. Cancer and Cell Penetrating Peptide

Cancer refers to a category of disorders in which cells have the capacity to multiply abnormally, with the capacity to penetrate and disseminate to additional body parts. 9.6 million cancer-related deaths were reported worldwide, and 18.1 million additional cases are anticipated in 2018. All throughout the world, the incidence and mortality rate of cancer, a chronic health problem, are rising quickly. The four cancers with the greatest prevalence rate are lung, breast, prostate, and colorectal, while the four malignancies that cause Pulmonary, colon, gastric, and hepatitis cancers cause the most cancer-related deaths. Cancer is a growing public health concern. Cancer does not only harm humans; it may also impact wildlife and many other species. The majority of the time, cancerous cells detach from this original grouping of cells, move via the lymphatic and circulatory systems, and then establish themselves in other organs where they can reactivate the unregulated growth period.

The use of traditional chemotherapeutic agents is severely constrained. For instance, when treating metastatic melanoma, the medications may cause additional malignancies or tumors may become resistant to treatment and relapse. Drugs that successfully treat low to the ground and resting cells without inducing chemo resistance mechanisms are still in great supply since they may specifically eliminate cancer cells. Researchers working on anti-cancer therapies are looking for a method to target cancer cells only, minimize side effects, avoid being impacted by typical chemo resistance mechanisms, and eliminate latent and slow-growing cells. (Smith et al.,2000).

1.2. Aim of the Project

This research focused on recent developments and potential uses of cell penetrating peptides as therapeutic agents for the treatment of malignancy. Researchers explore the use of peptides in targeted cancer therapy, both individually and combined with other peptides or comparatively tiny molecule cytotoxic agent. Also, we take into account the application, strategies and

limitations of peptides as a carrier for targeted molecular imaging in the detection and of cancer therapy.

1.3. Objective of this Study

The purpose of this study is

-to understand the purpose of this study is

- To shed light on the CPPs treatment strategies

-To comprehend the constraints and potential implications.

.

Chapter 02

Methodology

The information was gathered through peer reviewed papers that were publicized, research papers, and studies that were accessible in a variety of databases, including PubMed, Frontiers, MDPI, ScienceDirect, and Google Scholar etc. Significant keywords like cell penetrating peptides, CPP in cancer, etc. were applied to search papers. On the basis of the issue, relevant and resourceful articles were gathered, and additional context was examined. Following the selection of the topic, an outline was created with pertinent headings and subheadings. Medley Desktop provided the bibliography and in text citation. The entire essay was paraphrased, and thewriting contained citations.

Chapter 03

Cancer

The following are some general types of cancer-related or causing substances: radioactive materials, certain diseases, biochemical or cytotoxic chemical interactions, and genetics. In general, anything that has the potential to lead to a normal body cell developing uncontrollably is considered to be a cancer-related or causative agent. Although common signs and symptoms are not particularly selective, patients with various cancers may experience the following: exhaustion, losing weight, physical discomfort, skin changes, change in bowel or bladder function, unusual hemorrhaging, chronic cough or voice start changing, pyrexia, lumps or tissue masses. Damaged DNA is repaired by DNA repair genes. Cells with all these genetic variations frequently experience chromosomal duplications and deletions. These alterations might work together to turn the cells malignant. Many distinct malignancies frequently have suppressor gene mutations or deletions. (Regberg et al., 2012)

The key event in the development of cancer may be the loss of tumor suppressor gene function. The p53 is the best-known potent inhibitor of tumor to date, and it appears that the wild-type gene is necessary for preventing tumor development. A screening and assessment of potential cancerous tissue is examined to determine the exact diagnosis of cancer, despite the fact that there are numerous procedures that screen for and presumptively diagnose the condition. The type of cancer and the degree of disease dissemination are generally identified by the findings ofa biopsy; cancer stages also aid in the development of treatment regimens for patients and their caregivers (Bidwell & Raucher, 2009). Generally, more the invasive the cancer type or more the extensive the disease is throughout the body, the higher the number allocated (often between 0 and 4), in most staging techniques. Different cancers require different staging techniques, which should be individually explored with physician.

3.1. Traditional Treatments of Cancer

There are many different cancer therapies available. The phase and form of cancer a person has determines the type of treatment they will receive.

3.1.1. Chemotherapy

It may be the only form of treatment you receive in some cases. However, chemotherapy is typically combined with other cancer treatments. Chemotherapy inhibits or retards the cancer cells' rapid differentiation of cell and growth. it works in both ways to treat cancer, reduce the likelihood of its coming back to the treated person or delay its progress. Cancer symptoms might get reduced with chemotherapy that can be used to reduce tumors that are causing pain and other discomforting situation. Neoadjuvant chemotherapy is one kind of chemo where the tumor is reduced before doing the surgery when used with conjunction. It also eradicates any tumor cells that could still be present after radiation or surgery also kill cancercells that have returned or spread to other places of one’s body to make other therapies more effective.

3.1.2. Immunological Checkpoint Inhibitors

The system recognizes malignant cells, destroys them, and probably prevents or retards the development of many cancers. Immune cells can occasionally be found in and surrounding tumors. Cancer cells possess ways for escaping immune response eradication, even though the immune system can stop or limit the progression of cancer. Immunological checkpoint inhibitors are medications that can prevent the activity of immune checkpoints. They prevent overly powerful immune responses and are a typical component of the immune system. T-cell transfer therapy, a therapy that improves T cells' innate capacity to fight cancer. Immune cells are extracted from tumor and employed in this treatment.

3.1.3. Radiotherapy

It is utilized as a cancer treatment to eradicate cancer cells and reduce size of tumor. Cancer cells with irreparable DNA damage either stop reproducing or pass away. The body destroys and gets rid of the harmed cells after they pass away. Cancerous cells are not immediately eliminated by radiation therapy. Days or weeks of therapy are needed before DNAis sufficiently damaged to kill cancer cells. Cancer cells continue to die for a few weeks or months after radiation therapy is over.

3.1.4 Targeted Therapy

The proteins that control the multiplication, replication, and movementof tumor cells are the targets of targeted therapy. It is the foundation of personalized medicine.

3.2. CPP used in Cancer Therapy

The discovery of biological mechanisms that can successfully block in vitro has advanced significantly. Furthermore, because of difficulties with tumor targeting, toxicity, and functional activity in vivo, the safe, systemic distribution of these blocking medicines to patients has proved challenging and occasionally difficult. These obstacles have been removed by the recent invention of CPPs, which has resulted in the creation of innovative tumor-specific molecular therapies. A conjugated cargo can be transported throughout the plasma membrane with the help of CPPs, which are composed of short amino acid sequences. When CPP-associated payloads enter the cell, they can engage with their intracellular targets and counteract their tumor-causing abilities. The uptake of non-toxic cell technique is crucial because it enables the secure and efficient systemic delivery of treating cancer. The absence of toxicity of CPPs as compared to other cytoplasmic delivery mechanisms, such as liposome's, etc., is one advantage of employing them for therapeutic delivery. It has been reviewed that CPPs can transport a number of covalently or non-covalently attached payloads inside of living cells, containing nanoparticles as

peptides, proteins, antisense oligonucleotides, small interfering RNA and double-stranded DNA, liposome's, aGUPTA et al.,2005).Activable CPPs (ACPPs) were recently used in vivo to target cancer cells overexpressing metalloproteinase-2 (Olson et al.,2009), and the suppression of NF-jB was also effective in vivo when the antagonists were coupled to various peptides for the treatment of various inflammatory illnesses. Inhibiting NF-jB has been used to treat a variety of inflammatory disorders. (Orange &May.,2008). Examples of substances that can penetrate the central nervous system (CNS) and act on malignancies of this system, such as glioblastoma multiform, are TAT and Penetratin (GBM). These aforementioned peptides have also been demonstrated to trigger killing of apoptosis in mammary, lung and hepatic cancer cells when combined with conventional chemotherapy drugs like doxorubicin (DOX) and paclitaxel (PTX). (Liu et al.,2012) Strong anticancer effects were produced in various malignancies, including esophageal cancer, as a result of the association of Magainin 2 (MG2) with Bombesin (MG2B), another CPP, which includes esophageal cancer. Examples include CPP p28 and CopA3, which both specifically decreased the survivability of stomach cancer cells. Also, preclinical investigations involving breast cancer, ovarian cancer and colorectal cancer were used to evaluate this peptide's anti-tumor performance (Fuet al.,2015).

Table 1: Application of CPP

Cargo	CPP	Drug	Disease
Peptides	Penetratin	Insulin	Diabetes
Nano-particles	KALA peptide	VEGF-pDNA	Wound
Small molecules	Cyclic CPP	Cabazitaxel	Breast Cancer
Nucleic acid	CHAT	Luciferase- pDNA	-

Chapter 04

Historical Background of CPP

CPPs were initially discovered by research on preclinical studies, including Drosophila melanogaster (Antennapedia, Antp) and the Human Immunodeficiency Virus (HIV Tat) retrovirus. Since the discovery of CPPs, numerous investigations in this area have been carried out. Preliminary studies essentially focused on uncovering features and pathways and improving cellular absorptivity (Xu et al.2019). The earliest and most prevalent are the small amino acid sequences known as cationic CPPs, which also are primarily made up of the amino acids arginine, lysine, and histidine. These amino acids give the peptide its cationic charge, which is what, will allow it to interact with anionic motifs on the plasma membrane (Derossi et al., 1994). Amphipathic peptides, a second class of CPPs, are responsible for facilitating peptide translocation across the plasma membrane because of their hydrophilic and lipophilic tails. The idea of PTD was first put forth twenty years ago as a result of the discovery that some proteins, mostly transcription factors, may shuttle between and within cells. Historically, (Tat) protein of HIV-1 was first observed to be able to enter cells and move into the nucleus in 1988 by Frankel and Pabo. In 1991, the Prochiantz group demonstrated that neural cells may uptake the Drosophila Antennapedia homeodomain. (Joliot et al., 1991), work that served as the foundation for the 1994 discovery of the first PTD or CPP: a (RQIKIYFQNRRMKWKK) derived from the third helix of the Antennapedia homeodomain (Derossi et al., 1994**).**

4.1. Cell Penetrating Peptides based delivery of Cargos

The peptides, that have lengths around 5 to 30 amino acids can move through the plasmamembrane and carry cargo ranging from proteins and oligonucleotides to proteins and small molecules (such as DNA, siRNA, and plasmid) (Regberg et al.,2012). This makes them a promising method of drug delivery. These CPPs interact with peptides and help them enter the cell membrane; they are

hydrophobic in nature that is primarily made of basic residues (Bidwell&Raucher.,2009). Both energy-dependent (endocytosis and pinocytosis) and energy- independent (direct translocation) processes (Walrant et al.,2013) are used to take them up by the cell. The concentration of the peptides, the cell type (Fischer et al.,2004), the size of the carried cargo, and other variables all affect how well these peptides are internalized.



Figure 1: CPP and Cargo Association (Porosk & Langel, 2022)

The CPPs comprise anticipated and already known CPPs produced from proteins, as well as chimeric and synthetic CPPs. Cationic, primary and secondary amphipathic, and even negatively charged peptides are all represented in the CPP family of chemical delivery vectors. The CPPs may be changed to contain fatty acid residues, PEG additions, or non-proteogenic amino acid residues. Numerous moieties can be connected with the cargos that CPPs can carry, and they can also be employed to improve the internalization of NPs. Covalent relationships between CPP and the cargo, non-covalent associations, or the addition of CPP to mixtures without it associating with the components are the three types of associations. Numerous researches have used techniques including the cargo-CPP complex system, the non-covalent combination type distribution of different pharmaceuticals or nucleic acids, the active targeting approach, the synthesis of specific signal- activated CPPs, and the multipurpose integrating multiple properties (Kim et al.2021). Mouse models were used to confirm techniques in vivo.

Table 2: Example of CPPs

Peptide	Origin	Sequence
TAT (48–60)	Protein-derived	GRKKRRQRRRQC
pVEC	Protein-derived	LLIILRRRIRKQAHAHSK-NH_2
Transportan	Chimeric	GWTLNSAGYLLGKINLKALAALAKKIL-NH_2
PepFect3	Chimeric,Modified	Stearyl-AGYLLGKINLKALAALAKKIL-NH
MPG8	Chimeric	AFLGWLGAWGTMGWSPKKKRK-cya
Polyarginine	Designed	R_n (n = 6–12)
Pep-1	Designed	Ac-KETWWETWWTEWSQPKKKRKV-cya
Pep-3	Designed	KWFETWFTEWPKKRK-cya
YTA2	Designed	YTAIAWVKAFIRKLRK-NH_2
SynB1	Protein-derived	RGGRLSYSRRRFSTSTGR

4.2. CPP Classification

Basic groups of CPPs may be differentiated based on where they originated from peptides originating from proteins, chimeric peptides created by joining two different natural sequences, and synthetic CPPs, that are deliberately created sequence data that are based primarily on configuration analyses depending on the sequencing' physico-chemical properties, such as their hydrophobic nature or amphipathicity (Madani et al., 2011).

Table 3: Types of CPP

Type	Source	Example
Cationic	HIV Tat Protein	Tat
Amphipathic	Azurin	Azurin p28
Hydrophobic	Mastoparan and galanin	TP10
Cationic	Phage display	PTD-5
Amphipathic	Azurin	Azurin p18
Hydrophobic	Mastoparan and galanin	Transportan

4.3. Drug Loading Approaches with CPP

The two major classes of CPPs are those that require chemical connection with the medicine for intracellular administration and those that generate persistent, non-covalent drug combinations. CPPs have been effectively used to deliver pharmaceuticals, including liposomes, nucleotides, nanoparticles, proteins, and peptides, in both vivo and in vitro studies (Heitz et al., 2009)

4.3.1.Small Molecules

The medication doxorubicin (DOX) has been studied for its ability to induce apoptosis in cancer cells when conjugated with CPPs (DOX-CPPs) (Bolhassani, 2011). Breast cancer cell line MDA-MB-231 was discovered to be sensitive to apoptotic killing by DOX-CPPs (Qi et al., 2012). Even though DOX is a commonly used anticancer drug, it is only able to cross the blood-brain barrier (BBB), which is made up of endothelium junctions of the brain's capillaries. The ATP-dependent outflow mechanism P-glycoprotein (P-gp), which was initially identified as playing a role in the

multi - drug resistance (MDR) processes of malignant cells resistant strains, has also been shown to be present in the luminal site of the endothelial cells of the blood-brain barrier. P-gp may prevent cytotoxic medicines from getting into the brain (Rousselle et al., 2003). small naturally derived peptides with the capacity to penetrate the BBB have been employed as drug delivery vectors to circumvent DOX's restricted access to the brain. D-penetratin and SynB1 were covalently joined to DOX by these two peptides. The amount of DOX carried into the brain parenchyma was boosted 20-fold when DOX was coupled to either D-penetration or SynB1 vectors (Rousselle et al., 2000). Penetratin and TAT were covalently coupled to DOX in a different investigation as CPPs.CHO Cells,mammary cancer cells, HUVEC , Differentiated NG108-15 Neuronal Cells, MCF7 Drug-SensitiveCell Lines were used to assess the cytotoxicity, intracellular distribution, and internalization. Comparing the conjugates to free DOX revealed that they have various distribution inside the cell membrane patterns and cell killing activities. The cytotoxicity of DOX in CHO cells, HUVEC cells, and MDA-MB-231 cells was increased after treatment with DOX- CPPs. However, NG108-15 cells and MCF7 showed lower cytotoxicity (Aroui et. al.2019)

Table 4: CPP and cargoes of drug for therapy of tumor

CPP	Cargo	Method	Application
TAT, Penetratin, SynB1	DOX	Covalent coupling	Breast cancer cell lines MDA-MB-231
YTA2	MTX	Covalent coupling	Resistant breast cancer cells MDA-MB-231
YTA4	Fluorescein and MTX	Covalent coupling	Breast cancer cells MDA-MB-231

CADY	DOX	Non-covalent complex	Increased therapeutic index and blood residence time
TAT	P53	Covalent coupling	Rabbit eyes harboring human retinoblastoma xenograft
R8	SmacN7	Non-covalent coupling	Reversed apoptotic resistance
Antp	P16	Non-covalent coupling	Pancreatic cancer

Methotrexate (MTX), which works as a drug for cancer and with restricted use owing to tolerance issues, inhibits the production of purine nucleotide, the component parts of DNA, particularly in the cytoplasm by inhibiting the enzyme dihydrofolate reductase which stops the growth of tumors. The cell line MDA-MB-231 was obtained from an individual in alreadydeveloped MTX resistance after treatment. The conjugation of MTX to a CPP, YTA2 (MTX- YTA2), was investigated in MTX-resistant breast carcinoma cell physical model. The main pathway for cellular uptake of MTX occurs via reduced folate carrier (RFC), which is not expressed in this cell line. Both MTX transport defects and reduced MTX toxicity sensitivity were present in tumor cells. The EC50 values of MTX-YTA2 in the study of cell viability werefive times smaller than the results for MTX individually (Lindgren et al., 2006).The best way to administer various kinds of medicinal compounds might not always involve attaching CPPs to tiny particles. Covalent coupling to a peptide may prevent a medicine from attaching to a target or may impair the activity of physiologically active molecules like proteins and oligonucleotides.

4.3.2. Macro Molecules

Numerous in vivo studies have been conducted on the establishment of protein therapies driven by CPP-fused carcinogenic macromolecules. Using a Tat peptide made from the N-terminus of p53, other cancer suppressing and suicidal genes have been used. Several (Harada et al., 2002). The most frequent anti-apoptotic lesions in cancerous cells are the alteration of the p53 gene, which is present in 50% of human cancers (Harada et al., 2002). The p53 protein's N-terminal region was fused to the TAT (TAT-p53N), which caused a fast buildup of p53 and the activation of apoptotic genes (Harada et al., 2006). The peptide caused a large amount of tumor cell death after being injected Xenografted human retinoblastoma in rabbit cornea (Harada et al., 2006). However, the surrounding normal tissue was not significantly harmed. The cellular import of oligonucleotides and analogs can be accomplished without being harmful by using CPP (Bolhassani, 2011). SiRNA, ribozymes, or oligonucleotide analogues can regulate gene expression at the RNA level without affecting the nucleus, but their ability to do so is constrainedby their negative charge in cells (Patel et al., 2007). Shorter amphipathic peptides have recently been successfully used without a covalent manner to introduce therapeutic (siRNA) and (PNA) molecules (MPG8/PEP3). In a range of cancer cell lines, PEP3 and MPG8 boost their cellular absorption while preventing cytotoxic effects by synthesizing stable nanomaterials with PNA and siRNA, in particular, outside the endosomal channel.

A PNA coupled with transport protein 10 increased the passage of the PNA into the cytosol in the analysis of the relationship between RNA and RNA associated proteins. When crosslinked with cholesteryl-R9, siRNA against the multifunctional angiogenic growth factor also known as vascular endothelial growth factor (VEGF) was shown to increase tumor remission effectiveness including both in vitro and vivo.

A p65-derived peptide coupled with Antp was used in a newly authorized patent to prevent p65 from initiating transcription. Following exposure to the chemotherapeutic drug DOX, the Antp-

p65-1 treated leukemia cells also showed a rise in cytotoxic sensitivities, and exposes the cancer cells to death that are resistant to chemotherapy. Shepherdin, an intriguing peptide that was fused with the CPPs Antp or Tat, was created to resemble a tiny region of the surviving protein coupled Hsp90's ATPase component. Shepherdin resulted in loss of membrane permeability and caspase-dependent death. In addition, when shepherdin was used to treat breast and prostate cancers that had developed superficially in immune-compromised animals, the tumors' development was reduced in comparison to untreated mice (Bolhassani, 2011). The use of non-covalent complexes of CPP-oligonucletides that aren't bonded covalently to CPPs can be concluded to result in substantial cellular uptake and bioactivities (Patel et al., 2007).

Chapter 05

Internalization of CPPs

Penetratin, Tat peptide, and R9 are peptides that were first studied for their ability to enter cells in a passively, temperature- and receptor-independent manner that was resistant to endocytosis inhibitors (Rayne et al., 2010). The peptides may therefore be entering the cell directly through physical disruption of the plasma membrane, it was hypothesized.

5.1. Endocytosis: A possible entry point

Most cells naturally go through a process called endocytosis. non - covalent interactions with cellular proteoglycans or immediate connection with the plasma membrane can both initiate it. Electrostatic interactions with cell surface proteoglycans or direct contact with the plasma membrane can both initiate it. When attached to GAGs, CPPs may enter either more effectively or after the ongoing recycling process of GAGs that are constantly absorbed (Belting, 2003). Through the of GAGs agitation, stimulation of signaling molecules, and actin reconfiguration, CPPs can cause endocytosis (Jiao et al., 2009). Passage of the various CPPs, and primarily CPPs-cargo complexes, all known forms of pinocytic pathways were characterized.

Macropinocytosis: It has been shown that this process contributes to the internalization of poly arginine and to a much minor extent of penetratin (Nakase et al., 2004; Rejman et al.2009). According to a new case (Mishra et al., 2011), after the peptide is internalized with formation of pores, that engages with the actin cytoskeleton, which will cause macropinocytosis. However, according to some research, the peptides will activate the small GTPase Rac1 following the binding and clustering of proteoglycans, which will cause actin remodeling and trigger macropinocytosis (Kaplan et al., 2005).Dowdy group established macropinocytosis as the mechanism for Tat absorption, with the requirement signaling moleculesthat functioning proteins be present but not surface GAGs or sialic acids for the intake (Gump et al., 2010).

Table 5: Frequently used chemical endocytic antagonists

Inhibitor	Mode of Action
Hyperosmolar conditions	Dispersion of plasma membrane
Potassium depletion	Clathrin lattices
Amilorides	Inhibitors of Na/H exchange
Methyl-b-cyclodextrin	Cholesterol extraction
Statins	Inhibition of cholesterol synthesis
Chlorpromazine	Loss of clathrin and AP2 adaptor complex from the cell surface
Cytosolic acidification	Inhibits the budding of clathrin-coated pits

After being inhibited by hyperosmolar medium, clathrin-induced engulfing was found to be responsible as a means of penetrating uptake, Tat pep- time etc. (Säälik et al., 2004). Additionally, despite the fact that numerous studies showed the Tat peptide to be involved in clathrin- dependent endocytosis (Ter-Avetisyan et al., 2009), Caveolae-induced retention was also shown . for some of the peptides having cell penetrating property, such as the Tat peptide that co-localized with the caveolae identifier caveolin- (Ferrar et al., 2003), despite the conflicting findings of numerous other investigations. For example, the absorption of Tat peptide in baby rodent kidney cells was not affected by caveolin knock-out or the treatment of HeLa and Chinese hamster ovary (CHO) cells with nystatin and filipin III, antagonists of caveolae- dependent endocytosis (Richard et al., 2005).



Figure 2: CPP Internalization by Endocytosis (Janicka et al., 2019)

Cellular membrane instability results via direct translation and happens independently of energy and temperature. Direct translocation was initially suggested as the method of internalization of CPPs, then rejected as an artifact of fixation. Immediate transposition was initially suggested that method of incorporation of penetrating peptides inside the cell then rejected as a a fixing artifact. Direct translocation was later verified using fluorescence in living cells, analyzing of the intake at 4 °C and in the exclusion of engulfing (e.g., ATP depletion), and using other biophysical approaches in models (Bolhassani, 2011).It is possible for areas between distinct membrane domains to have wrapping issues that make them extra prone to the entry of peptides. entrance or to serve as nucleation sites which is porous.This reconfiguration of the membrane can result in the synthesis of these domains via thepeptide's preferential association with anion exchange. (Joanne et al., 2009).

5.2. Structural Considerations

It is generally recognized that basic CPPs bind electrostatically with anionic proteoglycans Figure 3: CPP Internalization by Endocytosis (Janicka et al., 2019) 21 proteoglycans and phospholipids on the cellular membrane constitutes the initial phase for cellular entrance, even though it is not

explicitly required for the cell's absorption (Tiriveedhi & Butko, 2007). The cationic charge and the bonding of hydrogen, density, overall Shape, also including conformational changes of the peptides all exert significant control over how the distinct plasma membrane parts, whether electrostatic or hydrophobic, connect between themselves (Millettie.2012).

5.2.1. Positive Charge

The positive charges CPPs' probable primary encounter with the cellular membranes is of an electrostatic origin, during which the peptides attach to the negatively charged lipids and polysaccharides prior proceeding towards the internalization-active membrane receptors. In addition, Ryser and Hancock discovered how mixing albumin with high molecular weight poly-lysines increased the consumption of the protein by tumors, demonstrating the importance of the positive charge in boosting macromolecule uptake(Ryser & Hancock, 1965). The significance of positively charged proteins was subsequently demonstrated for several CPPs combinations.

5.2.2. Hydrophobicity

It is considered that hydrophobic residues, which are important in their interactions with the plasma phospholipid bilayer, facilitate the translocation of peptides across this membrane (Takayama et al., 2009). In addition, any single residue changes to the pVEC peptide's N-terminal hydrophobic region (LLILL) resulted in a reduction in the CPP's cellular absorption (Elmquist et al., 2006). In contrast , introducing a tryptophan residue or a fluorescein isothiocyanate (FITC) dye to the unmarked segments of the R6 and Tat peptide caused vesicle spillage, demonstrating that alterations in hydrophobic nature had a significant impact on the translocation pathway.

5.2.3. Peptide Secondary Structure

To understand the alteration of the transmembrane and subsequent uptake, the structure and composition of CPPs was primarily investigated when they interacted with modeling membrane

surface. After interacting with lipids, CPPs, which are largely unstructured in aqueous solution (Magzoub et al., 2003) take on a variety of forms. Even for a similar sequencing, this heterogeneity is undoubtedly the results of the various experimental parameters used, including temperature, peptide/lipid quantities and proportions, buffering environments and others. Tat and shorter poly arginines are unstructured when in association with model membranes, while penetratin has been demonstrated to assume an a-helical shape and a b-strand conformation. Whether a link exists between a peptide's secondary structure and its translocational properties isstill up for debate. Nevertheless, significance of constructional flexibility, as highlighted by the Divita team, who stated that structural polymorphism and malleability of CPPs might be vital for the membrane association and internalization channel (Deshayes et al., 2008), and also prefer the peptide favoring a pathway of access over the other by their structure (Eiríksdóttir et al., 2010).

5.3. CPPs-based Approaches to Target Cancer Cells

There are several techniques for targeting c with CPPs and particular ligands for selectively targeting cancer cells, with CPPs coupled with specific ligands. Activated CPPs are intended to be unresponsive until they are stimulated by cancer specific enzymes, and transducible agents are intended to be controlled in hypoxic tumors but degrade in healthy tissue. Cell attacking peptides are typically created by combining a traditional CPP pattern with a tumor cell attacking peptide.

5.3.1. Activable CPP

A recent class of potential molecular diagnostic markers for the detection of enzymatic processes, ACPPs are novel in vivo tracking agents that also consist of a polycationic cell-penetrating

peptide (CPP) coupled to a neutral polyanion via a cleavable linker (Olson et al., 2009). Inhibiting electrostatic attraction and lowering the total charge to almost zero, this structure prevents absorption inside cells (Bolhassani, 2011). Thus, intramolecular ionic interactions with apeptide containing multiple anionic charge is able to effectively prevent a polycationic peptide from reaching cells.



Figure 3: Schematic diagram of Activable CPPs (Gao et al., 2014

The polycationic cell-penetrating peptide and the polyanionic peptide can be separated via proteolysis, which also permits the activating cell-penetrating peptide to move into the cell (Olson et al., 2009). Certain proteins disrupt the linkage tying the polyanionic and polycationic domains combined, allowing for cell penetration (Olson et al., 2009). The particular proteases can be utilized to target cancer-related enzymes. The targeted activation of CPPs within the

pathogenic surroundings of tumors is enhanced by stimulus-responsive substances in ACPPs. Recently, cancer associated proteases (CAPs) have received much interest as a novel approach to targeted delivery of tumors. A group of proteases known as CAPs are often absent or found in very small quantities in healthy cells, but they are frequently greatly up-regulated in malignant cells. Urokinase plasminogen activator (uPA), a number of matrix metalloproteinases (MMPs), and certain cathepsins are examples of CAPs that have been studied. MMPs are a class of proteolytic enzymes (Polette et al., 2004). and are likely one of most researched CAPs for tumor-responsive delivery of drugs (Zhang et al., 2012). In the majority of carcinomas, host stromal cells manufacture the majority of the MMPs, and their expression suggests tight collaboration between both the cancer and stroma cells (Polette et al., 2004). In the majority of carcinomas, host stromal cells manufacture the majority of the MMPs, and their expression suggests tight collaboration between both the cancer and stroma cells (Polette et al., 2004)

Tumor cells have the ability to express a variety of MMPs., and they are thought to be important agents helping tumor cells spread during metastasis (Deryugina & Quigley, 2006). As a result, MMPs offer a favorable candidate for medication delivery systems that target cells containing tumors. Because MMPs are a type of cleavable enzyme which is related with malignant disorders (Qi et al., 2012) and have exhibited excess development in several kinds of human cancers (Zhang et al., 2012), the ACPP method could also be employed to improve anticancer medicines for tumor-targeting treatments. Elevated MMP transcription has been linked to poor patient outcomes in a variety of malignancies, including mammary (MMP-11) and colorectal (MMP-1) cancer. Additionally, in a variety of tumor forms, the expression of particular MMPs has been used as a predictive indication of treatment outcomes and an indicator of tumorigenesis (Zhang etal., 2012). Tissue therapy has made use of the production of an ACPP compound with the anticancer medication doxorubicin (DOX), which is susceptible to matrix metalloproteinase-2 and -9 (MMP 2/9). MMP-2/9 can stimulate the ACCP-DOX conjugate, permitting the active

CPP-DOX to enter cells. A novel peptide termed NoPe, which stands for "zero cellular penetrating," is a hybrid peptide that's also based on the CPP YTA4 and has been given an activated region and a linker for protease MMP-2 in order to accomplish delivery particularly. NoPe is a dormant inactivated-form of YTA4 that MMP-2 may specifically cleave and activate. In the study fluoresceiny attached to NoPe is specifically deposited inside the tumor sites in MDA-MB-231 mice that have tumors after IV injection of peptide conjugates of fluoresceinyl carboxylic acid (Mäe et al., 2012).and a cytosprotective drug MTX, This method worked well in- vivo.

5.3.2. Cell Targeting Peptides

For treating cancer, cell-targeting peptides (CTPs) that can identify cancer cells are particularly alluring for their targeted distribution (Bolhassani, 2011). In a laboratory experiment, the use of these peptides improved medication delivery's specificity and effectiveness while minimizing adverse effects (Zhang et al., 2012). The cyclic peptide PEGA termed as homing peptide has been shown previously to develop in mouse breast carcinoma tissue. Various breast cancer cells absorbed PEGA molecular peptide coupled to the cell-penetrating peptide pVEC in vitro. Moreover, the PEGA-homing pVEC's ability remained preserved in vivo, in which the conjugate primarily concentrates in blood vessels in breast tumor tissue (Kersemans & Cornelissen, 2010). Additionally, it has been demonstrated that conjugating chlorambucil to pVEC-PEGA increases the anticancer drug's effectiveness by a factor of nearly four (Myrberg et al., 2007), decreasing the clonogenic lifespan of MCF-7 cell lines (Kersemans & Cornelissen, 2010). A further sample of a homing peptide is the linear 5-amino acid long peptide CREKA, which was discovered in breast cancers in MMTV-PyMT treated mice (Mäe et al., 2008). Although it has not been demonstrated to internalize into tumor cells, the CREKA peptide identifies clogged membrane proteins and selectively attaches to fibrin-like complexes in tumor vascular system and stroma. Through one trial, CREKA was administered as a chimeric peptide along with the CPP pVEC (Bolhassani,

2011).

In comparison PEGA-pVEC peptides disclosed previously, this novel peptide, CREKA-pVEC, is easier to produce and, is more effective at delivering cargo molecules into cancerous cells(Mäe et al., 2008). CREKA-pVEC is an effective vehicle for delivering a DNA alkylating chemical to specific intracellular targets. To create nano-vectors for extremely effective gene transfer to cancer cells, the specified receptorfolic acid (FA) also the peptide named octaarginine (R8) were added to the genetic carrier (PEI (600)-CyD, PC) (Bolhassani, 2011). Attributable to the combined application of folic receptor-initiated enterocytes and membrane activity the derived ternary nano-complexes of FA-PC/R8-PC/pDNA resulted extremely good gene delivery qualities in folic acid receptor favorable tumors in vivo and in vitro (Jiang et al., 2011). By building CPPs containing peptides or antibodies that serve as targets, intracellular or intracytoplasmic addressing can be done in a cell-specific manner. Radiolabeled peptides with the DEVDGsequence were presented in the initial publication to describe the usage of a CPP-targeting label design. Furthermore, TAT-peptide associated anti-p21 antibodies were discovered through the analysis of radiolabeled TAT-antibody combinations. The Fc terminal of IgG was selectively coupled with radioiodinated TAT-peptides. Since such TAT-peptide sequencing contains a nuclear localization domain, it was demonstrated that these radio-immuno constructs could translocate to the nucleus and bind to p21, a cyclin-dependent kinase blocker and growth controller.

Table 6: An overview of a targeting sequence paired to a CPP for targeted delivery to tissues or tumors

Targeting Peptide	Active Sequence	Target Site
PEGA	CPGPEGAGC	Tumor blood vessels
CREKA	CREKA	Tumor blood vessels and stroma
DEVDG	DEVDG	Caspase3
DV3	LGASWHRPDKG	CXC chemokine receptor 4

5.3.3. Transducible Agents

The body of a cancer patient is covered in numerous cancers, administration of drugs against cancer necessary. Preliminary in situ research revealed that Tat proteins are carried to a variety oftissues after intraperitoneal (IP) insertion, suggesting that transducible medications may be able to be systemically distributed to a malignant tumor or multiple metastases (Snyder & Dowdy, 2004). A recombinant peptid that is specifically stabilized in hypoxic tumor cell was created in order to generate a therapeutic potential protein medication that is fairly specific for tumors (Harada et al., 2002). The uncontrolled proliferation (Harada et al.,2006) and increased metabolicrequirements of cancerous cells, which also are attributed directly to genetic changes in tumor cells, result in the formation of hypoxic site in tumors (Harada et al., 2006). The oxygen tensionin hypoxic areas is substantially lower than that in healthy cells. These increase radiation a nd treatment for cancer opposition (Harada et al., 2002). Angiogenesis and glycolysis-related genetic mutations are stimulated by the transcriptional factor hypoxia inducible factor-1 (HIF-1), the key regulator of the hypoxic reflex (Bolhassani, 2011). This process makes malignant cells more invasive and spreadable (Harada et al., 2006).

Anti-Gal Ab (a–d) and X-gal staining (e–f) were used to measure the detection of-Gal protein and enzymatic activity in the liver.Oxygen-dependent destruction (ODD)-galactosidase (-Gal), a model fusion protein, is constituted of a portion of the ODD domain of hypoxia-inducible factor- 1 linked to -Gal.



Figure 5: TAT-ODD-Gal fusion protein degrades quickly in healthy tissue (Koshikawa & Takenaga, 2005)

The pharmacologically active fusion protein was preferentially localized in cancers but was scarcely perceptible in normal tissue after ODD—Gal was subsequently combined to the HIV-TAT protein transduction domain (TAT 47-57) and IP infused in animal having tumors (Harada et al., 2002). Only the cells' hypoxic areas exhibited TAT-ODD-Gal protein footprints. On the other hand, after IP administration, TAT-galactosidase protein could have been observed across malignancies (Qi et al., 2012).

5.4. Cell-Penetrating Peptides Mechanism

The cationic amino acids that make up CPPs, like lysine or arginine, combine to form a peptide sequence that is very strongly positively charged. These positively charged sequences have the capacity to engage in receptor-independent interactions with acidic motifs on the plasma membrane. Proteoglycans and glycolipids are just two examples of the many substrates with acidic patterns that can be discovered on the plasma membrane (Duchardt et al., 2007). In order to enhance the effectiveness of this interaction and ultimately the peptide's cytosolic translocation, a current discovery described the usage of synthetic CPP, PTD-SN1. The peptides internalize after interacting with these substrates in a cell-type independent manner. Although the precise mechanism of this internalization process is yet unknown, it is dependent on a number of peptide characteristics, particularly the kind of CPP and the cargo's structure and charges. According to a latest report, the internalization of Antp and Tat CPP can be facilitated by macropinocytosis, clathrin-dependent endocytosis, caveolin-dependent endocytosis, or rapid intracellular translocation (Duchardt et al., 2007). The CPP-tagged treatment (CTT) resists lysosomal decomposition after being internalized by endosomes through an unexplained mechanism. To transfer therapeutic doses of CTTs to the cytosol, endosomal leakage is understood to be the rate-limiting process (Edenhofer, 2008). The CTT can contact its receptor effectively after it has been delivered through into cytosol. It has been proven in vitro that a CPP (Tat) connected medication enters the cell and begins to impact its target around five minutes of such therapy (Wadia et al., 2004).



Figure 5: Mechanism of Peptide Membrane Transduction (Bitler & Schroeder, 2010)

Peptide Membrane Transduction Mechanism:

The tumor site receives CPP-Cargo peptide. The extracellular proteoglycans (left) or glycolipids (right) are in contact with the strongly cationic amino acid residues of the CPP. There seems to be indications that the CPP-cargo penetrates the cell directly (center arrow). The peptide is endocytosed by clathrin or caveolae, Peptides endosomal leakage occurs therefore contacting with targeted protein.

5.4.1. Cell-Penetrating Peptides with Anticancer Mechanism

Following the discovery of the initial peptide transmission domains, anti-cancer treatments(CTTs) have increasingly been delivered to the cytosol and nuclear compartments through CPPs.

The promise of CTTs for the treatment of lymphoid cancer and, colon, pancreatic, mammary ovarian and hepatic malignancies has been extensively documented in publications and patents during the past ten years (Harada et al., 2006). CTTs have indeed been utilized in anti-cancer therapy to suppress oncoprotein nuclear translocation, modify oncoprotein activation, and prevent exchanges between cells and the ECM that promote metastasis. Throughout most instances, the technique of inhibition is essentially the same: a target association is identified, and part or all of the interacting protein is attached to a CPP. To prevent endogenous pro-cancerous contacts, the CTT is subsequently transduced throughout the plasma membrane and transported to the cytosol or nucleus.



Figure 6: CPPs Anti-Cancer Mechanism (Bitler & Schroeder, 2010)

CTT's anti-cancer therapy mechanism:

The ECM interaction is primarily inhibited by the CPP component of the CTT, which adheres to the

plasma membrane that blocks cancer cells that have propagated to secondary tumor locations from doingso. CTTs prevent the cancer-dependent protein-protein interactions that stop angiogenesis, proliferation, and chemoresistance. Interacting protein suppression can also affect the oncogenic transcriptional elements' nuclear translocation.

5.5. Limitations and Current Development

CTTs have now been employed to create sensitivity to radioactivity and chemotherapy treatments. Despite the fact that it has taken some time to make the transition from the laboratory to the clinic, current developments should support this translation.

Stability Modification- The possible consequences of serum proteases on peptide breakdown prior to intracellular localization is one challenge with employing peptides as medications. Incubation with SDS or polysialic acid, that has been demonstrated to improve peptide stabilization and circulation all through the blood (Schutze-Redelmeier et al., 1996), could be used as a potential modification to CTTs. A larger level of therapeutic peptide could be maintained by preventing serum protease activity in the circulation. Yi et al. reported that human serum samples treated with heparin or citrate are able to stabilize the peptides present in the serum (Yi et al., 2008), The modification of amino-acid isomerization can be another method for maintaining peptides in the circulatory system. This method may have a significant impact on the bioavailability and effectiveness of peptides.

One possible issue with CTTs is that they are often small peptides that effectively eliminate them from the body through the kidneys so have poor tumor absorption. Another research used a hydrophilic polyethylene glycol covering to serve as an effective "macromolecular drug delivery carrier" to resolve this issue (Prego et al., 2005). The disadvantages of addressing with a CTT alone have recently been addressed by the use of nanoparticles to deliver medications that are macromolecules, such as peptides and genes (de la Fuente et al., 2008). These transporters will

work by enclosing the therapy in a "capsule," enabling target tissues to receive substantially higher doses of CTT despite mucosal barrier.

Chapter 06

6.1. Discussion

CPP-based administration is a prospective method for delivering cancer drugs due to its capacity to transfer cargoes inside the cell. Traditional chemotherapeutic drugs and contemporary gene- based medicines may both be able to reach tumor cells. Another benefit is the potential to create targeted delivery systems by fusing fragments of peptides peptide for cell penetration with the targeting ones. Similar to this, activated CPPs can be constructed by joining protective multiple negative charges with linkers with cleavable property that are unique to the target. The peptide transforms into an active CPP when this linker is severed. With CPPs coupled with targeting ligands, there are numerous methods for selectively targeting cancer cells. Combining a regular CPP sequencing with a cancer targeting peptide typically results in cell targeting peptides. ACPPsare meant to be latent as cell-penetrating peptides unless triggered by catalyst particular to the cancer. Transducible substances remain persistent in tumors with low oxygen levels but degrade in healthy tissue.

Oncology and the mechanism underlying oncogenesis are becoming highly complicated. Potential treatment strategies have been found as new facets of biomedical research were explored. Now, a handful of patents that propose to use CPPs to deliver anti-cancer medicines targeted at these unique targets have been issued. A current invention highlights a miRNA manufacturing protein as a possible therapeutic target(Viswanathan et al., 2008). Other patent proposes for using CPPs to emphasize on epigenetics, a novel area of human cancer. Another patent proposes to use CPPs to focus on a novel aspect of cancer biology called epigenetics. The application of a CPP to transport an antisense nucleic acid to stop the translation of a splice variation of DNA methyltransferase 3B, which has been demonstrated to cause hypermethylation and gene silencing in carcinoma, is specifically described in this patent (Alves et al., n.d.). Two phases make up the endocytosis of CPPs: endocytic entrance, accompanied by endosomal escape. Enhanced therapeutic levels in the cytoplasm will be achievable if endosomal escape could be optimized, boosting the CTT/target contact. Yet, several of

the trials looked at in this study reveal that the tumor still has a sizable quantity of CTT hours following injection. The higher bioavailability of the target found inside tumor cells is one theory for why this phenomenon occurs. According to the CTT's interaction withits target, it cannot be weakened (Thorén et al., 2000).

6.2. Future Aspects

CPPs finally appear to be prepared to go from the bench to clinical applications after several years ofdevelopment. Due to the current paucity of therapeutically viable drug carriers and the adverseeffects of many medicines, the field of cancer therapeutics will probably be among the first to gainfrom the usage of CPPs. CPPs may also be used in combination delivery systems based on liposomalformulations or other kinds of nanoparticles. The blood-brain barrier can be crossed with the help ofnanoparticles modified with CPPs, and they may also be more precise in their distribution whenpaired with penetrating/targeting peptides. The most frequent cancer types, such as adeno-carcinomacell cancer and mammary cell are the major prospects for recent therapies due to the high expensesof putting a medicine into clinical usage, but applying these in other cancer types. The high stability of peptide-based dosage forms, when compared to many other drug administration techniques suchas liposomes, will be a key advantage of this therapy approach. Overall, CPPs have a promising future, and the first CPP-drugs will likely be available in the few years.

Chapter7

Conclusion

As disruption to the cell membrane, transporters, or conveyors is not necessary for entry into the cell, CPP bound medicines offer a new strategy for treating cancer in a selective and non-toxic approach. In this discussion, we learnt about naturally existing and enhanced protein transduction domains and how to use them to transport anti-cancer treatments to damaged cells' intercellular space. We discussed studies that have actually obtained or are awaiting patents, whose functionality has been established and published for extremely bright prospects of these therapies for the treatment of malignancy. In conclusion, the utilization of CTTs in the treatment of cancer is a young area with a lot of unexplored territory. Conversely, due to their low toxic effects, limited immune system alteration, tissue specificity, capacity to target the majority of interactions that promote cancer, and modulation of oncogenic signaling, CTTs look promising in the area of cancer immunotherapy. This review's discussion of treatment strategies and patents represents a insight of the potential these peptides have to treat cancer.

Bibliography

Alves, I. D., Walrant, A., Bechara, C., & Sagan, S. (n.d.). *Is There Anybody in There? On The Mechanisms of Wall Crossing of Cell Penetrating Peptides*. http://www.eurekaselect.com. Retrieved January 31, 2023, from https://www.eurekaselect.com/article/47529

Aroui, S., Brahim, S., Waard, M. D., & Kenani, A. (2010, January). Cytotoxicity, intracellular distribution and uptake of doxorubicin and doxorubicin coupled to cell-penetrating peptides indifferent cell lines: A comparative study. *Biochemical and Biophysical Research Communications*, *391*(1), 419– 425. https://doi.org/10.1016/j.bbrc.2009.11.073

Aguilera, T. A., Olson, E. S., Timmers, M. M., Jiang, T., & Tsien, R. Y. (2009, May 11). Systemic vivo distribution of activatable cell penetrating peptides is superior to that of cell penetrating peptides. *Integrative Biology*, *1*(5–6), 371–381. https://doi.org/10.1039/b904878b

A. R., Scherrmann, J. M., & Temsamani, J. (2003, April 7). Improved Brain Uptake and Pharmacological Activity of Dalargin Using a Peptide-Vector-Mediated Strategy. *Journal of Pharmacology and Experimental Therapeutics*, *306*(1),371–376. https://doi.org/10.1124/jpe t.102.048520

Belting, M. (2003, March). Heparan sulfate proteoglycan as a plasma membrane carrier. *Trends in Biochemical Sciences*, *28*(3), 145–151. https://doi.org/10.1016/s0968-0004(03)00031-8

Bitler, B. G., Menzl, I., Huerta, C. L., Sands, B., Knowlton, W., Chang, A., & Schroeder, J. A. (2008, December 31). Intracellular MUC1 Peptides Inhibit Cancer Progression. *Clinical Cancer Research*, *15*(1), 100–109. https://doi.org/10.1158/1078-0432.ccr-08-1745

Bidwell, G. L., & Raucher, D. (2009, July 29). Therapeutic peptides for cancer therapy. Part I – peptide inhibitors of signal transduction cascades. *Expert Opinion on Drug Delivery*, *6*(10), 1033–1047. https://doi.org/10.1517/17425240903143745

Bolhassani, A. (2011, December). Potential efficacy of cell-penetrating peptides for nucleic acid and

drug delivery in cancer. *Biochimica Et Biophysica Acta (BBA) - Reviews on Cancer*, https://doi.org/10.1016/j.bbcan.2011.07.006

Drin, G., Cottin, S., Blanc, E., Rees, A. R., & Temsamani, J. (2003, August). Studies on the Internalization Mechanism of Cationic Cell-penetrating Peptides. *Journal of Biological Chemistry, 278*(33), 31192–31201. https://doi.org/10.1074/jbc.m303938200

Duchardt, F., Fotin-Mleczek, M., Schwarz, H., Fischer, R., & Brock, R. (2007, May 10). A Comprehensive Model for the Cellular Uptake of Cationic Cell-penetrating Peptides. *Traffic,8*(7), 848– 866. https://doi.org/10.1111/j.1600-0854.2007.00572.x

Edenhofer, F. (2008, December 1). Protein Transduction Revisited: Novel Insights Into the Mechanism Underlying Intracellular Delivery of Proteins. *Current Pharmaceutical Design*, *14*(34), 3628–3636. https://doi.org/10.2174/138161208786898833

Elmquist, A., Hansen, M., & Langel, L. (2006, June). Structure–activity relationship study of the cell-penetrating peptide pVEC. *Biochimica Et Biophysica Acta (BBA) - Biomembranes, 1758*(6), 721– 729. https://doi.org/10.1016/j.bbamem.2006.05.013

F. (2012, March 23). *Cell-penetrating peptides: classes, origin, and current landscape*. Cell-penetratingPeptides: Classes, Origin, and Current Landscape - ScienceDirect. Retrieved January 30, 2023, from https://www.sciencedirect.com/science/article/abs/pii/S1359644612000839

Fawell, S., Seery, J., Daikh, Y., Moore, C., Chen, L. L., Pepinsky, B., & Barsoum, J. (1994,January 18). Tat-mediated delivery of heterologous proteins into cells. *Proceedings of the National Academy of Sciences, 91*(2), 664–668. https://doi.org/10.1073/pnas.91.2.664

FUTAKI, S. (2005, February 28). Membrane-permeable arginine-rich peptides and the translocation mechanisms. *Advanced Drug Delivery Reviews*, *57*(4), 547–558.https://doi.org/10.1016/j.addr.2004.10.009

Ferrari, A., Pellegrini, V., Arcangeli, C., Fittipaldi, A., Giacca, M., & Beltram, F. (2003, August). Caveolae-Mediated internalization of extracellular HIV-1 tat fusion proteins visualized in real time.

Molecular Therapy, *8*(2), 284–294. https://doi.org/10.1016/s1525-0016(03)00122-9

Fischer, R., Köhler, K., Fotin-Mleczek, M., & Brock, R. (2004, March). A Stepwise Dissection of the Intracellular Fate of Cationic Cell-penetrating Peptides. *Journal of Biological Chemistry*, *279*(13), 12625–12635. https://doi.org/10.1074/jbc.m311461200

Fu, H., Shi, K., Hu, G., Yang, Y., Kuang, Q., Lu, L., Zhang, L., Chen, W., Dong, M., Chen, Y.,& He, Q. (2015, March). Tumor-Targeted Paclitaxel Delivery and Enhanced Penetration Using TAT-Decorated Liposomes Comprising Redox-Responsive Poly(Ethylene Glycol). *Journal of Pharmaceutical Sciences*, *104*(3), 1160–1173. https://doi.org/10.1002/jps.24291

Guterstam, P., Madani, F., Hirose, H., Takeuchi, T., Futaki, S., EL Andaloussi, S., Gräslund, A., & Langel, L. (2009, December). Elucidating cell-penetrating peptide mechanisms of action for membrane interaction, cellular uptake, and translocation utilizing the hydrophobic counter-anion pyrene butyrate. *Biochimica Et Biophysica Acta (BBA) - Biomembranes*, *1788*(12), 2509–2517. https://doi.org/10.1016/j.bbamem.2009.09.014

GUPTA, B., LEVCHENKO, T., & TORCHILIN, V. (2005, February 28). Intracellular deliveryof large molecules and small particles by cell-penetrating proteins and peptides. *Advanced Drug Delivery Reviews*, *57*(4), 637–651. https://doi.org/10.1016/j.addr.2004.10.007

Harada, H., Kizaka-Kondoh, S., & Hiraoka, M. (2006, January). Antitumor protein therapy; Application of the protein transduction domain to the development of a protein drug for cancer treatment. *Breast Cancer*, *13*(1), 16–26. https://doi.org/10.2325/jbcs.13.16

Heitz, F., Morris, M. C., & Divita, G. (2009, March 20). Twenty years of cell-penetrating peptides: frommolecular mechanisms to therapeutics. *British Journal of Pharmacology*, *157*(2), 195–206. https://doi.org/10.1111/j.1476-5381.2009.00057.x

Harada, H., Hiraoka, M., & Kizaka-Kondoh, S. (2002, April 1). *Antitumor Effect of TAT- Oxygen-dependent Degradation-Caspase-3 Fusion Protein Specifically Stabilized and Activated in Hypoxic Tumor Cells*. American Association for Cancer Research. Retrieved January 30, 2023, from https://aacrjournals.org/cancerres/article/62/7/2013/509786/Antitumor-Effect-of-

TAT-Oxygen-dependent

Jiang, Q. Y., Lai, L. H., Shen, J., Wang, Q. Q., Xu, F. J., & Tang, G. P. (2011, October). Genedelivery totumor cells by cationic polymeric nanovectors coupled to folic acid and the cell- penetrating peptide octaarginine. *Biomaterials*, *32*(29), 7253–7262. https://doi.org/10.1016/j.biomaterials.2011.06.015

Jiao, C. Y., Delaroche, D., Burlina, F., Alves, I. D., Chassaing, G., & Sagan, S. (2009, December). Translocation and Endocytosis for Cell-penetrating Peptide Internalization. *Journal of Biological Chemistry*, *284*(49), 33957–33965. https://doi.org/10.1074/jbc.m109.056309 Gump,

J. M., June, R. K., & Dowdy, S. F. (2010, January). Revised Role of Glycosaminoglycans in TAT Protein Transduction Domain-mediated Cellular Transduction. *Journal of Biological Chemistry*, *285*(2), 1500–1507. https://doi.org/10.1074/jbc.m109.021964

Kaplan, I. M., Wadia, J. S., & Dowdy, S. F. (2005, January). Cationic TAT peptide transductiondomain enters cells by macropinocytosis. *Journal of Controlled Release*, *102*(1), 247–253. https://doi.org/10.1016/j.jconrel.2004.10.018

Kersemans, V., & Cornelissen, B. (2010, March 11). Targeting the Tumour: Cell PenetratingPeptides for Molecular Imaging and Radiotherapy. *Pharmaceuticals*, *3*(3), 600–620. https://doi.org/10.3390/ph3030600

Lindgren, M., Rosenthal-Aizman, K., Saar, K., Eiríksdóttir, E., Jiang, Y., Sassian, M., Östlund, P., Hällbrink, M., & Langel, L. (2006, February). Overcoming methotrexate resistance in breast cancer tumour cells by the use of a new cell-penetrating peptide. *Biochemical Pharmacology*, *71*(4), 416–425. https://doi.org/10.1016/j.bcp.2005.10.048

Liu, R., Xi, L., Luo, D., Ma, X., Yang, W., Xi, Y., Wang, H., Qian, M., Fan, L., Xia, X., Li, K., Wang, D., Zhou, J., Meng, L., Wang, S., & Ma, D. (2012, August). Enhanced targeted anticancer effects and inhibition of tumor metastasis by the TMTP1 compound peptide TMTP1-TAT-NBD. *Journal of Controlled Release*, *161*(3), 893–902. https://doi.org/10.1016/j.jconrel.2012.05.002

Madani, F., Lindberg, S., Langel, L., Futaki, S., & Gräslund, A. (2011, April 7). Mechanisms Cellular Uptake of Cell-Penetrating Peptides. *Journal of Biophysics*, *2011*, 1–10. https://doi.org/10.1155/2011/414729

Majumdar, S., & Siahaan, T. J. (2010, September 2). Peptide-mediated targeted drug delivery. *Medicinal Research Reviews*, *32*(3), 637–658. https://doi.org/10.1002/med.20225

Magzoub, M., Eriksson, L., & Gräslund, A. (2003, March). Comparison of the interaction, positioning, structure induction and membrane perturbation of cell-penetrating peptides and non-translocating variants with phospholipid vesicles. *Biophysical Chemistry*, *103*(3), 271–288. https://doi.org/10.1016/s0301-4622(02)00321-6

Mishra, A., Lai, G. H., Schmidt, N. W., Sun, V. Z., Rodriguez, A. R., Tong, R., Tang, L., Cheng, J., Deming, T. J., Kamei, D. T., & Wong, G. C. L. (2011, October 3). Translocation of HIV TAT peptide and analogues induced by multiplexed membrane and cytoskeletal interactions. *Proceedings of the National Academy of Sciences*, *108*(41), 16883–16888. https://doi.org/10.1073/pnas.1108795108

MAE, M., & LANGEL, U. (2006, October). Cell-penetrating peptides as vectors for peptide,protein and oligonucleotide delivery. *Current Opinion in Pharmacology*, *6*(5), 509–514. https://doi.org/10.1016/j.coph.2006.04.004

Meade, B. R., & Dowdy, S. F. (2008, March). Enhancing the cellular uptake of siRNA duplexes following noncovalent packaging with protein transduction domain peptides. *Advanced Drug Delivery Reviews*, *60*(4–5), 530–536. https://doi.org/10.1016/j.addr.2007.10.004

Mäe, M., EL Andaloussi, S., Lundin, P., Oskolkov, N., Johansson, H. J., Guterstam, P., & Langel, L. (2009, March). A stearylated CPP for delivery of splice correcting oligonucleotidesusing a non-covalent co-incubation strategy. *Journal of Controlled Release*, *134*(3), 221–227. https://doi.org/10.1016/j.jconrel.2008.11.025

Mäe, M., Rautsi, O., Enbäck, J., Hällbrink, M., Aizman, K. R., Lindgren, M., Laakkonen, P., & Langel,

L. (2012, June 27). Tumour Targeting with Rationally Modified Cell-Penetrating Peptides. *International Journal of Peptide Research and Therapeutics*, *18*(4), 361–371. https://doi.org/10.1007/s10989-012- 9312-1

Nakase, I., Niwa, M., Takeuchi, T., Sonomura, K., Kawabata, N., Koike, Y., Takehashi, M., Tanaka, S., Ueda, K., Simpson, J. C., Jones, A. T., Sugiura, Y., & Futaki, S. (2004, December). Cellular Uptake of Arginine-Rich Peptides: Roles for Macropinocytosis and Actin Rearrangemet.

Olson, E. S., Aguilera, T. A., Jiang, T., Ellies, L. G., Nguyen, Q. T., Wong, E. H., Gross, L. A.,& Tsien,

R. Y. (2009, May 11). In vivo characterization of activatable cell penetrating peptides for targeting protease activity in cancer. *Integrative Biology*, *1*(5–6), 382–393. https://doi.org/10.1039/b904890a

Orange, J. S., & May, M. J. (2008, August 1). Cell penetrating peptide inhibitors of Nuclear Factor-kappa B. *Cellular and Molecular Life Sciences*, *65*(22), 3564–3591. https://doi.org/10.1007/s00018-008-8222-z

Polette, M., Nawrocki-Raby, B., Gilles, C., Clavel, C., & Birembaut, P. (2004, March). Tumor invasion and matrix metalloproteinases. *Critical Reviews in Oncology/Hematology*, *49*(3), 179– 186. https://doi.org/10.1016/j.critrevonc.2003.10.008

Patel, L. N., Zaro, J. L., & Shen, W. C. (2007, April 19). Cell Penetrating Peptides: Intracellular Pathways and Pharmaceutical Perspectives. *Pharmaceutical Research*, *24*(11), 1977–1992. https://doi.org/10.1007/s11095-007-9303-7

Prego, C., García, M., Torres, D., & Alonso, M. (2005, January). Transmucosal macromolecular drug delivery. *Journal of Controlled Release*, *101*(1–3), 151–162.https://doi.org/10.1016/j.jconrel.2004.07.030

Qi, X. R., Shi, Gao, & Xiang. (2012, March). Enhancing cellular uptake of activable cell- penetrating peptide–doxorubicin conjugate by enzymatic cleavage. *International Journal of Nanomedicine*, 1613. https://doi.org/10.2147/ijn.s30104

Rayne, F., Debaisieux, S., Bonhoure, A., & Beaumelle, B. (2010, March 12). HIV-1 Tat is unconventionally secreted through the plasma membrane. *Cell Biology International*, *34*(4), 409–413. https://doi.org/10.1042/cbi20090376

Ryser, H. J. P., & Hancock, R. (1965, October 22). Histones and Basic Polyamino Acids Stimulate the Uptake of Albumin by Tumor Cells in Culture. *Science*, *150*(3695), 501–503. https://doi.org/10.1126/science.150.3695.501

Richard, J. P., Melikov, K., Vives, E., Ramos, C., Verbeure, B., Gait, M. J., Chernomordik, L. V., & Lebleu, B. (2003, January). Cell-penetrating Peptides. *Journal of Biological Chemistry*

Regberg, J., Srimanee, A., & Langel, L. (2012, September 12). *Applications of Cell-PenetratingPeptidesfor Tumor Targeting and Future Cancer Therapies*. MDPI. Retrieved December 27, 2022, from https://www.mdpi.com/1424-8247/5/9/991

Rousselle, C., Clair, P., Smirnova, M., Kolesnikov, Y., Pasternak, G. W., Gac-Breton, S., Rees, Säälik, P., Elmquist, A., Hansen, M., Padari, K., Saar, K., Viht, K., Langel, L., & Pooga, M. (2004,October 1). Protein Cargo Delivery Properties of Cell-Penetrating Peptides. A Comparative Study. *Bioconjugate Chemistry*, *15*(6), 1246–1253.https://doi.org/10.1021/bc049938y

Snyder, E. L., & Dowdy, S. F. (2004, March). Cell Penetrating Peptides in Drug Delivery.
Pharmaceutical Research, *21*(3), 389–393. https://doi.org/10.1023/b:pham.0000019289.61978.f5

Smith, L. L., Brown, K., Carthew, P., Lim, C. K., Martin, E. A., Styles, J., & White, I. N. H. (2000, January). Chemoprevention of Breast Cancer by Tamoxifen: Risks and Opportunities. *Critical Reviewsin Toxicology*, *30*(5), 571–594. https://doi.org/10.1080/10408440008951120

Schutze-Redelmeier, M. P. M., Kong, S., Bally, M. B., & Dutz, J. P. (2004, May). Antennapedia transduction sequence promotes anti tumour immunity to epicutaneously administered CTL epitopes. *Vaccine*, *22*(15–16), 1985–1991. https://doi.org/10.1016/j.vaccine.2003.10.028 *Chemistry*, *277*(4), 2437–2443. https://doi.org/10.1074/jbc.m110017200

Schwarze, S. R., & Dowdy, S. F. (2000, February). In vivo protein transduction: intracellulardelivery of biologically active proteins, compounds and DNA. *Trends in Pharmacological Sciences*, *21*(2), 45–48. https://doi.org/10.1016/s0165-6147(99)01429-7

Tiriveedhi, V., & Butko, P. (2007, March 1). A Fluorescence Spectroscopy Study on the Interactions of the TAT-PTD Peptide with Model Lipid Membranes. *Biochemistry*, *46*(12), 3888–3895. https://doi.org/10.1021/bi602527t

Thorén, P. E., Persson, D., Karlsson, M., & Nordén, B. (2000, October 5). The Antennapedia peptide penetratin translocates across lipid bilayers - the first direct observation. *FEBS Letters*,*482*(3), 265–268. https://doi.org/10.1016/s0014-5793(00)02072-x

Takayama, K., Nakase, I., Michiue, H., Takeuchi, T., Tomizawa, K., Matsui, H., & Futaki, S. (2009, September). Enhanced intracellular delivery using arginine-rich peptides by the addition of penetration accelerating sequences (Pas). *Journal of Controlled Release*, *138*(2), 128–133. https://doi.org/10.1016/j.jconrel.2009.05.019

Tan, M., Lan, K. H., Yao, J., Lu, C. H., Sun, M., Neal, C. L., Lu, J., & Yu, D. (2006, April 1). Selective Inhibition of ErbB2-Overexpressing Breast Cancer In vivo by a Novel TAT-Based ErbB2-Targeting Signal Transducers and Activators of Transcription 3–Blocking Peptide. *Cancer Research*, *66*(7), 3764–3772.https://doi.org/10.1158/0008-5472.can-05-274

Thorén, P. E., Persson, D., Karlsson, M., & Nordén, B. (2000, October 5). The Antennapedia peptide penetratin translocates across lipid bilayers - the first direct observation. *FEBS Letters*,*482*(3), 265–268. https://doi.org/10.1016/s0014-5793(00)02072-x

Ter-Avetisyan, G., Tünnemann, G., Nowak, D., Nitschke, M., Herrmann, A., Drab, M., &Cardoso, M. C.(2009, February 6). *Cell Entry of Arginine-rich Peptides Is Independent of Endocytosis* *. Journal of Biological Chemistry. Retrieved January 31, 2023, from https://www.jbc.org/article/S0021- 9258(19)81748-9/abstract.